The readiness of psychiatrists to implement psychedelic-assisted psychotherapy
This pilot mixed-methods study of psychiatrists in one NHS mental health trust found widespread familiarity with and majority support for controlled therapeutic use of psychedelics, with trainees better informed than non‑training-grade psychiatrists. Despite positive attitudes, clinicians across grades reported low preparedness to deliver psychedelic-assisted psychotherapy and identified substantial training needs and wider societal and professional uncertainties as barriers to implementation.
Authors
- Page, L.
- Rehman, A.
- Syed, H.
Published
Abstract
Introduction
Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients. This pilot study examined the attitudes and knowledge of NHS psychiatrists of all levels towards psychedelic-assisted psychotherapy and explored potential barriers and facilitators to its implementation.
Methods
A mixed-methods approach was adopted, using a cross-sectional survey and focus groups. All psychiatrists in one NHS mental health trust were approached by email to participate. The survey was analysed using a simple descriptive approach and thematic analysis was used for the focus groups.
Results
Eighty-three (25.7%) psychiatrists participated in the survey. All psychiatrists were familiar with one or more psychedelic substances. Although 77.2% felt that there should be a role for controlled or therapeutic use of psychedelics, trainees appeared better informed than non-training grade psychiatrists. Psychiatrists of all grades did not feel prepared to participate in the delivery of psychedelic-assisted psychotherapy. Thematic analysis of the focus groups identified three main themes in relation to psychedelic-assisted psychotherapy: “need for knowledge,” “openness to change,” and “uncertainty.”Discussion: NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise. However, psychiatrists are lacking in confidence or preparedness to implement this treatment should it become a mainstream option and significant training needs were identified. Thematic analysis highlighted the need for societal shifts as well as professional ones.
Research Summary of 'The readiness of psychiatrists to implement psychedelic-assisted psychotherapy'
Introduction
Psychedelic-assisted psychotherapy (PAP) is emerging as a promising treatment approach in psychiatry, with growing research interest particularly for depressive disorders, cancer-related anxiety and alcohol dependence. Classical psychedelics are serotonergic hallucinogens that act via 5-HT2A receptor agonism and are increasingly framed as relatively safe, low-abuse-potential medicines with rapid therapeutic effects. Despite accumulating clinical trial evidence and regulatory attention (for example, psilocybin’s FDA “breakthrough therapy” designation in 2019), it is unclear whether the clinical workforce is prepared to provide PAP in routine services. Murnane and colleagues designed a pilot study to assess the awareness, knowledge and attitudes of National Health Service (NHS) psychiatrists towards PAP, and to identify perceived barriers and facilitators to its implementation within a nationalised healthcare system. The study focused on classic hallucinogens (LSD, psilocybin, mescaline, etc.), deliberately excluding related agents such as MDMA and ketamine, and combined a cross-sectional survey with focus groups to capture both quantitative breadth and qualitative depth of views. Secondary aims included exploring whether demographic factors such as age or training grade related to preparedness to deliver PAP.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Page, L. A., Rehman, A., Syed, H., Forcer, K., & Campbell, G. (2021). The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.743599
References (15)
Papers cited by this study that are also in Blossom
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Show all 15 referencesShow fewer
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Nielson, E. M., Guss, J. · Journal of Psychedelic Studies (2018)
Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)
Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)
Cited By (2)
Papers in Blossom that reference this study
Barnett, B. S., Arakelian, M., Beebe, D. et al. · Psychedelic Medicine (2024)
Herrmann, Z., Levin, A. W., Cole, S. P. et al. · Psychedelic Medicine (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.